rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Analyses of the EGFR mutation in separately microdissected specimens from adenocarcinoma and spindle cell components revealed that both components possessed the L858R point mutation.
|
21556797 |
2011 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Analyses of the EGFR mutation in separately microdissected specimens from adenocarcinoma and spindle cell components revealed that both components possessed the L858R point mutation.
|
21556797 |
2011 |
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Analyses of the EGFR mutation in separately microdissected specimens from adenocarcinoma and spindle cell components revealed that both components possessed the L858R point mutation.
|
21556797 |
2011 |
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Both sporadic and germline T790M mutations were predominantly adenocarcinomas, favored female gender, and were occasionally multifocal.
|
24736066 |
2014 |
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Cytological examination of the pleural effusion confirmed an adenocarcinoma positive for the <i>EGFR</i> exon 19 deletion and the T790M mutation within exon 20, while a biopsy from the upper left bronchus revealed a keratinizing squamous cell carcinoma positive for the <i>EGFR</i> exon 19 deletion.
|
29113230 |
2017 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
EGFR L858R was more frequently harbored in the MP+ adenocarcinoma patients than in the MP- adenocarcinoma patients.
|
31732945 |
2020 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
EGFR L858R was more frequently harbored in the MP+ adenocarcinoma patients than in the MP- adenocarcinoma patients.
|
31732945 |
2020 |
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
EGFR L858R was more frequently harbored in the MP+ adenocarcinoma patients than in the MP- adenocarcinoma patients.
|
31732945 |
2020 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
EGFR mutations (ex19del and L858R) were detected in 1759/8716 (20.2 %) adenocarcinomas, 28/669 (4.2 %) squamous cell carcinomas (SCC) and 8/119 (6.7 %) large cell carcinomas.
|
27259329 |
2016 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
EGFR mutations (ex19del and L858R) were detected in 1759/8716 (20.2 %) adenocarcinomas, 28/669 (4.2 %) squamous cell carcinomas (SCC) and 8/119 (6.7 %) large cell carcinomas.
|
27259329 |
2016 |
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
EGFR mutations (ex19del and L858R) were detected in 1759/8716 (20.2 %) adenocarcinomas, 28/669 (4.2 %) squamous cell carcinomas (SCC) and 8/119 (6.7 %) large cell carcinomas.
|
27259329 |
2016 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Eighteen out of 20 large cell carcinomas, not otherwise specified, had glandular differentiation upon immunohistochemistry, with an exon 21 L858R EGFR mutation in one (5 %) tumor, an exon 2 KRAS mutation in eight (40 %) tumors, and an ALK translocation in one (5 %) tumor, whereas two tumors positive for CK7 and CK5/6 and negative for all other markers were considered adenocarcinoma.
|
24221342 |
2014 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Eighteen out of 20 large cell carcinomas, not otherwise specified, had glandular differentiation upon immunohistochemistry, with an exon 21 L858R EGFR mutation in one (5 %) tumor, an exon 2 KRAS mutation in eight (40 %) tumors, and an ALK translocation in one (5 %) tumor, whereas two tumors positive for CK7 and CK5/6 and negative for all other markers were considered adenocarcinoma.
|
24221342 |
2014 |
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Eighteen out of 20 large cell carcinomas, not otherwise specified, had glandular differentiation upon immunohistochemistry, with an exon 21 L858R EGFR mutation in one (5 %) tumor, an exon 2 KRAS mutation in eight (40 %) tumors, and an ALK translocation in one (5 %) tumor, whereas two tumors positive for CK7 and CK5/6 and negative for all other markers were considered adenocarcinoma.
|
24221342 |
2014 |
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Exon 20 T790M point mutation (T790M) was detected in 3 squamous carcinomas and 3 adenocarcinomas and exon 20 insertion mutation (20-ins) was detected in 2 patients with adenocarcinoma.
|
24351833 |
2013 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Expert consensus guidelines have defined minimum requirements for routine testing and identification of classical epidermal growth factor (EGFR) mutations (ie, exon 19 deletions and exon 21 L858R substitution) and anaplastic lymphoma kinase (ALK) rearrangements in advanced non-small-cell lung cancers of adenocarcinoma histology, with the intent of permitting use of these predictive biomarkers to select patients who will derive maximal benefit from approved oral tyrosine kinase inhibitors (TKIs) directed against EGFR and ALK, respectively.
|
27381270 |
2016 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Expert consensus guidelines have defined minimum requirements for routine testing and identification of classical epidermal growth factor (EGFR) mutations (ie, exon 19 deletions and exon 21 L858R substitution) and anaplastic lymphoma kinase (ALK) rearrangements in advanced non-small-cell lung cancers of adenocarcinoma histology, with the intent of permitting use of these predictive biomarkers to select patients who will derive maximal benefit from approved oral tyrosine kinase inhibitors (TKIs) directed against EGFR and ALK, respectively.
|
27381270 |
2016 |
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Expert consensus guidelines have defined minimum requirements for routine testing and identification of classical epidermal growth factor (EGFR) mutations (ie, exon 19 deletions and exon 21 L858R substitution) and anaplastic lymphoma kinase (ALK) rearrangements in advanced non-small-cell lung cancers of adenocarcinoma histology, with the intent of permitting use of these predictive biomarkers to select patients who will derive maximal benefit from approved oral tyrosine kinase inhibitors (TKIs) directed against EGFR and ALK, respectively.
|
27381270 |
2016 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Finally, we showed that EGFR(L858R)/Rhob(+/+) mice developed mainly diffuse lung tumors with a lepidic pattern, whereas EGFR(L858R)/Rhob(+/-) and EGFR(L858R)/Rhob(-/-) developed a greater number of tumors, and aggressive adenocarcinomas with invasive properties.
|
25320360 |
2014 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Finally, we showed that EGFR(L858R)/Rhob(+/+) mice developed mainly diffuse lung tumors with a lepidic pattern, whereas EGFR(L858R)/Rhob(+/-) and EGFR(L858R)/Rhob(-/-) developed a greater number of tumors, and aggressive adenocarcinomas with invasive properties.
|
25320360 |
2014 |
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Finally, we showed that EGFR(L858R)/Rhob(+/+) mice developed mainly diffuse lung tumors with a lepidic pattern, whereas EGFR(L858R)/Rhob(+/-) and EGFR(L858R)/Rhob(-/-) developed a greater number of tumors, and aggressive adenocarcinomas with invasive properties.
|
25320360 |
2014 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Herein, we report a case of 2 synchronous lung adenocarcinomas composed of 2 distinct pathological subtypes with different EGFR mutations: homozygous deletion in exon 19 in the papillary subtype of adenocarcinoma and a point mutation of L858R in exon 21 in the tubular adenocarcinoma.
|
18186961 |
2007 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Herein, we report a case of 2 synchronous lung adenocarcinomas composed of 2 distinct pathological subtypes with different EGFR mutations: homozygous deletion in exon 19 in the papillary subtype of adenocarcinoma and a point mutation of L858R in exon 21 in the tubular adenocarcinoma.
|
18186961 |
2007 |
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Herein, we report a case of 2 synchronous lung adenocarcinomas composed of 2 distinct pathological subtypes with different EGFR mutations: homozygous deletion in exon 19 in the papillary subtype of adenocarcinoma and a point mutation of L858R in exon 21 in the tubular adenocarcinoma.
|
18186961 |
2007 |
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
However, after completing 6 cycles of this combination, new pulmonary and hepatic metastases appeared and showed persistence of the original EGFR- and FGFR3-mutated ADC phenotype together with acquisition of the erlotinib-resistant T790M EGFR-mutation.
|
29110841 |
2017 |